Twist Bioscience CAO sells 800 shares for taxes

Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported a small mandated stock sale to cover taxes.

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported a small mandated stock sale to cover taxes. On the transaction date, he sold 800 shares of common stock in an open-market transaction at an average price of $62.484 per share.

According to the footnote, this sale was required to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After this sale, Werner directly holds 48,186 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 800 shares

Net Sell 1 txn

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Sold 800 shs ($50K)

Type	Security	Shares	Price	Value
Sale	Common Stock	800	$62.484	$50K

Holdings After Transaction: Common Stock — 48,186 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 800 shares Average sale price: $62.484 per share Shares held after transaction: 48,186 shares

3 metrics

Shares sold 800 shares Open-market sale on reported transaction date

Average sale price $62.484 per share Price for the 800-share sale

Shares held after transaction 48,186 shares Direct ownership after the sale

Key Terms

Restricted Stock Units, tax withholding obligations, sell to cover, equity incentive plans

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

sell to cover financial

"funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"mandated by the Issuer's election under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) disclose for Robert F. Werner?

Twist Bioscience disclosed that Chief Accounting Officer Robert F. Werner sold 800 shares of common stock. The sale was reported as an open-market transaction and was tied to tax withholding for Restricted Stock Unit vesting under the company’s equity incentive plans.

How many Twist Bioscience (TWST) shares did the CAO sell and at what price?

Robert F. Werner sold 800 shares of Twist Bioscience common stock at an average price of $62.484 per share. This transaction was used to cover tax withholding obligations associated with the vesting of his Restricted Stock Units.

Why did the Twist Bioscience (TWST) CAO sell 800 shares of stock?

The 800 shares were sold to cover tax withholding obligations from the vesting of Restricted Stock Units. The footnote explains these sales are mandated under Twist Bioscience’s equity incentive plans as a “sell to cover” transaction, not a discretionary trade by the officer.

How many Twist Bioscience (TWST) shares does Robert F. Werner hold after the sale?

After the tax-related sale, Robert F. Werner directly holds 48,186 shares of Twist Bioscience common stock. This post-transaction holding figure comes from the Form 4 and shows his remaining direct ownership position following the 800-share sale.

Was the Twist Bioscience (TWST) insider sale by the CAO discretionary?

No, the filing states the sale was not discretionary. The footnote clarifies it was mandated by Twist Bioscience’s equity incentive plans as a “sell to cover” transaction to fund tax withholding arising from Restricted Stock Unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S		800(1)	D	$62.484	48,186	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)